home All News open_in_new Full Article
Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars
today 1 week ago attach_file Other
attach_file
Politics
attach_file
Other
attach_file
Society
attach_file
Economics
attach_file
Economics
attach_file
Other
attach_file
Society
attach_file
Economics
attach_file
Economics
attach_file
Other
attach_file
Economics
attach_file
Sport
attach_file
Other
attach_file
Technology
attach_file
Other
ID: 3977811553